Prospective Randomized Controlled trial of low dose long term Peg-Interferon alpha-2a treatment after curative ablation for Hepatocellular Carcinoma.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 28 Jun 2017
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ursodeoxycholic acid
- Indications Hepatitis C; Liver cancer
- Focus Therapeutic Use
- 22 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 05 Nov 2007 New trial record.